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Abstract
Tardive dystonia due to D2 antagonists or other agents is a potentially severe extrapy-
ramidal side effect emerging after long-term drug treatment, prevalent but not limited 
to psychiatric populations. Its course is often deteriorating, and available treatments are 
frequently far from satisfying. It presents with sustained muscle contractions, abnormal 
postures, and repetitive twisting movements and leads to increased psychiatric morbid-
ity, mortality, and decline of quality of life. Inadequate clinical skill and awareness of tar-
dive dystonia can lead to neglect or misdiagnoses, considered as conversion symptoms or 
of psychogenic origin. Since the syndrome is persistent and often treatment resistant, pre-
vention should be a mainstay of clinical care. Emerging evidence supports positive effects 
of atypical antipsychotics, particularly quetiapine and clozapine. Therapies such as tet-
rabenazine, valbenazine, deutetrabenazine, anticholinergics, baclofen, benzodiazepines, 
vitamin E, or non-pharmacologic interventions, namely botulinum toxin A, deep-brain 
stimulation, have been found to be helpful in some cases of tardive dystonia. This chapter 
comprehensively illustrates multiple aspects of this entity, including recent advances on 
etiology, pathophysiology, clinical presentation, epidemiology, pharmacogenomics, and 
treatment, aiming to enhance and deepen clinicians’ and researchers’ awareness of tar-
dive dystonia, with the final goal of ameliorating patients’ prognosis and quality of life.
Keywords: tardive syndromes, tardive dyskinesia, tardive dystonia, antipsychotics, 
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1. Introduction
With the advent of antipsychotic drugs in the 1950s, a new era in the treatment of schizophre-
nia began, one that substantially altered the course of the illness and offered many benefits 
to patients and the society. Along with therapeutic advance, new troubles emerged, as it was 
soon realized that neuroleptics caused important side effects, among which drug-induced 
movement disorders could be seriously problematic. Tardive syndromes, largely represented 
by tardive dyskinesia and tardive dystonia, still remain challenging in many respects.
“Dystonia Tarda” was a term firstly used in 1973 to define a dystonia which appeared as a 
delayed undesirable effect in patients exposed to neuroleptic drugs [1]. Case descriptions 
appear in the literature even earlier, but a definition of the term “Tardive Dystonia” came 
from Burke et al. [2] who also implemented diagnostic criteria. The syndrome consists of 
involuntary, sustained muscle contraction(s), usually slow, often painful, affecting the face, 
neck, limbs, or trunk [3]. The involuntary muscle contractions can cause abnormal postures 
and twisting movements, which are often disfiguring and socially awkward.
Tardive dystonia (TDt) belongs to a constellation of persistent motor and sensory syndromes, 
collectively called tardive syndromes (TS), manifesting as a result of dopamine receptor 
blocking agents (DRBAs) or, less often, by other types of drugs (Figure 1). Tardive dyskinesia 
(TDk) was the first to be observed, in the 1950s, typically comprising rhythmic, repetitive 
oro-buccal-lingual involuntary movements, which, however, can also appear in trunk, limbs, 
and pelvis [4]. Later, TDt was also described as a distinct, frequently co-occurring or indepen-
dently manifesting condition. Although the term “tardive” implicates a long exposure and 
Figure 1. Tardive syndromes occurring in neuroleptic-treated patients. *Tardive parkinsonism is not solidly established, 
but probably signals the presence or unmasking of idiopathic parkinsonism. **Tardive pain refers to chronic oral or 
genital pain and is considered by some authors as a type of tardive akathisia, with a severe focal sensory discomfort.
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delayed onset, tardive syndromes can actually show up even days after the administration 
of the offending agent, notwithstanding that risk increases with longer exposure durations. 
Another important feature is their persistent nature, meaning that they persist or even worsen 
following discontinuation of the offending drug [5].
Progress in the field has demanded much effort, regarding the clinical recognition of the syn-
drome, pathophysiology, prevention, and treatment. One reason for this is that TDt often 
occurs simultaneously or as a component of TDk, or other tardive syndromes, and researchers 
have difficulties to deal with it separately. Moreover, there is often some confusion in the 
study, as authors may sometimes use the term tardive dyskinesia in order to refer to a variety 
of tardive syndromes. Much work examines tardive syndromes in general, and it is difficult 
to extract data referring specifically to TDt. Still, the distinction and separate examination of 
TDt is important, because it differs from TDk in respects of presentation, course, prognosis, 
and treatment; it is frequently more debilitating and treatment resistant; it is associated with 
a poorer quality of life, a reduced treatment compliance, and psychiatric morbidity [6–8]. 
Another task is to differentiate tardive dystonia from acute dystonia, emerging acutely and 
within days after the initial administration of anti-D2 agents, predominantly in young males, 
as well as from other types of dystonia. Tardive syndromes due to anti D2 agents are sche-
matically depicted in Figure 1.
In their pioneering work, Adityanjee et al. had hoped that tardive dystonia together with tar-
dive dyskinesia would in the future be a matter of historical interest, thanks to the advent of 
new, better antipsychotics [6]. Almost 20 years later, these movement disorders are not at all 
lost, not yet forgotten. Continuing to be a serious burden, they call for better understanding, 
prompt recognition, prevention, and optimized treatment.
2. Epidemiology
The prevalence of TDt has been estimated between 0.4 and 21.6% of neuroleptic-treated 
patients, in earlier studies [6], which distinguished tardive dystonia from tardive dyskinesia 
(Table 1). Most of them have included chronically ill patients. The study by Sethi et al. [13] 
was conducted on a veteran sample and also included mild manifestations of TDt, which is 
possibly the reason for the relatively high reported prevalence. Moreover, in a sample of 194 
mainly Afro-Caribbean chronic psychotic patients, TDt was overall found in 13.4%, together 
with TDk in 9.8%, together with parkinsonism in 4.6%, and together with akathisia in 1% 
of patients [17]. To compare, the prevalence of TDk, which is the most frequently observed 
tardive syndrome, has been reported to be 20–40% by a recent review [3].
More recently, the CATIE trial examined the efficacy, tolerability, and cost-effectiveness of 
the first- and second-generation antipsychotics and has provided some epidemiological data 
for extrapyramidal side effects, including TDk and/or TDt. The proportion of patients who 
met modified Schooler-Kane tardive dyskinesia criteria ranged from 8.3 to 9.6% with Second 
Generation Antipsychotics (SGAs) and 11.8% for perphenazine. There were no statistically 
significant differences between treatment groups on any TD indicator [18], but TDk was not 
discriminated from TDt by the researchers.
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A difficult question to answer is the differential risk of getting TDt after the administration of 
first- (typical) and second-generation (atypical) neuroleptics, when studies are conducted on 
subjects who have lifetime histories of exposure to both. A recent Korean study has attempted 
to deal with this issue [19]. The authors retrospectively and cross-sectionally examined the 
incidence and prevalence of TDt, apart from TDk, in 80 non-elderly (mean age ± SD: 33.1 ± 8.2) 
psychotic patients receiving SGAs, who were never treated with typical neuroleptics. The 
median time of exposure to antipsychotics was 66.8 months, 73.0, 58.8, and 88.0 months 
for patients without TDt or TDk, patients with only TDk, both, and only TDt, respectively. 
The sample was exposed at the onset of dystonia or previously to risperidone, amisulpride, 
olanzapine, aripiprazole, clozapine, ziprasidone, and quetiapine, with the most frequently 
prescribed antipsychotic being risperidone (72.5% of the subjects). Other received agents were 
benzodiazepines, antidepressants, and mood stabilizers. TDt was determined by applying the 
Burke criteria, at two separate examinations, and was observed in 13 patients, 8 of whom also 
had TDk. Prevalence was calculated to be 14.1% (11 out of 78 patients, since 2 were referred to 
the center for TDt). Tardive oculogyric crises occurred in another six. When only moderately 
and severely affected patients were included, prevalence dropped at 5.1%, which is similar 
to the prevalence estimated earlier, in the context of typical neuroleptics exposure (mean 
5.3%) [20]. TDt and TDk were significantly associated (p = 0.021). A history of acute dystonia 
significantly increased the risk for TDt (p < 0.001). Having comorbid obsessive compulsive 
symptoms was also significantly associated (p = 0.024), but when corrected for clozapine use, 
which could provoke obsessive compulsive symptoms and be used for the treatment of TDt, 
significance weakened (p = 0.074).
In a similar line, Lee et al. estimated the incidence and prevalence of tardive syndromes in a 
sample of psychotic patients (n = 123, mean age ± SD: 45.6 ± 13.8) exposed to antipsychotics for 
a period of at least 6 months, excluding those receiving a long list of other agents implicated 
in tardive syndrome occurrence, which is antidepressants, reserpine, tetrabenazine, methyl-
dopa, lithium, calcium-channel blockers, anticholinergics, and others [21]. The prevalence of 
TDt was 12.2%, with TDk being 21.1% and overall tardive syndrome prevalence 28.5%. The 
prevalence of nonremitting TDt was 7.3% and tardive syndrome 15.5%. A longer duration of 
Study Number of neuroleptic exposed patients Tardive dystonia prevalence (%)
Yassa et al. [9] 351 2
Yassa et al. [10] 558 1.6
Friedman et al. [11] 331 1.5
Chiu et al. [12] 917 0.04
Sethi et al. [13] 125 21.6
Inada et al. [14] 716 2.1
Sachdev et al. [15] 100 1
Raja [16] 200 4
Table 1. Early studies examining the prevalence of tardive dystonia.
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symptoms and more severe extrapyramidal symptoms (EPS) predicted nonremission of tar-
dive syndromes in general. Risk factors for the emergence of tardive syndromes were EPS and 
physical illness (stroke, diabetes mellitus, hepatitis, chronic pain, cancer, and other chronic ill-
nesses, e.g., hypertension, hyperthyroidism, renal stone, gastric ulcer, hyperlipidemia, benign 
tumor such as ovarian tumor and uterine myoma, and heart disease), but odd ratios were not 
calculated specifically for TDt. No difference in risk was found comparing first- generation 
antipsychotics (FGAs) to SGAs.
Moreover, in another retrospective study, Lee et al. set out to calculate the prevalence of tardive 
movement disorders in patients receiving antidepressants [22]. Out of 158 subjects, exposed 
to antidepressants for at least 6 months, but not to other agents causing tardive syndromes, 
14% had at least one tardive syndrome and 10.4% manifested TDt. Non-remitted TDt was 
5.1%. Notably, TDk was found at a lower rate (3.2%). Other tardive syndromes were tardive 
tremor (1.3%), tardive parkinsonism (1.3%), tardive tics (1.3%), tardive sensory syndrome 
(1.3%), and tardive myoclonus (0.6%). Patients exhibiting tardive syndromes had received 
SSRIs (fluoxetine, paroxetine, and escitalopram), SNRIs (venlafaxine and duloxetine), TCAs 
(amitriptyline and trazodone), NaSSA (mirtazapine), and NDRI (bupropion). The use of 
SNRIs and previous marriage significantly increased the risk of tardive syndrome occurrence, 
but the authors again do not differentiate between syndromes. Apart from this study, there 
are only few case reports linking antidepressant use with TDt [22–24], and, therefore, solid 
conclusions must await further studies.
The Genetic Risk and Outcome of Psychosis (GROUP) study is a prospective, naturalistic 
study on a large, relatively young (age: 27 ± 7 years; illness duration: 4 ± 4 years) cohort 
during 3 years of antipsychotic treatment. Drug-related movement disorders (DRMDs) as 
well as a variety of clinical outcomes were studied. The aim of the authors was to study the 
incidence, prevalence, and persistence rates of DRMDs at an early stage of the psychotic ill-
ness (schizophrenia and other non-affective psychoses), without prior treatment confounding 
[25]. Eligible patients for inclusion in the prevalence, incidence, and persistence analyses were 
828 at baseline (age: 27 ± 7, illness duration, mean: 4 ± 4 years) and 447 at follow-up. The 
prevalence of the DRMDs other than parkinsonism and akathisia did not differ significantly 
between patients treated with FGAs and SGAs, neither between olanzapine and risperidone, 
the two most frequently prescribed SGAs. Prevalence at baseline, 3-year follow-up, and 3-year 
incidence of TDt were 1.5, 1.8, and 1.6%, respectively. The incidence of TDt was low, probably 
due to a modest cumulative antipsychotic exposure in this population and in line with some 
previous reports (0–0.7%).
The rising prevalence of TDt in later retrospective and cross-sectional studies, compared to 
earlier ones, might reflect better recognition, the use of standardized tools and criteria, and 
lower symptom severity thresholds for the diagnosis. Indeed, in a study by Lee et al., when 
prevalence is calculated based only on moderately and severely ill patients, the estimation 
diminishes to 5.3%, similar to older studies reporting 0.4–4% [21]. Commenting data on FGAs 
and SGAs, it seems that the initial expectations in the beginning of the atypical antipsychotics 
era of banishing TDt and other tardive syndromes once and for all are far from being fulfilled. 
Still, TDt due to SGAs, albeit of similar prevalence, is possibly milder and more likely to remit 
(50 vs. 33% for SGAs and FGAs, respectively) [21].
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Summing up risk factors for TDt, mostly established ones are younger age, male sex [20], 
longer duration and higher doses of antipsychotic exposure, mood disorders, brain injury, 
mental retardation, dental procedures, diabetes mellitus, alcohol and substance abuse, and 
a previous acute dystonic reaction [3, 6, 8]. It has been reported that the presence of TDk 
increases the risk of TDt by 8.7 times [17]. Males tend to have a younger age at onset of TDt 
than females [5].
3. Offending drugs
Offending drug is considered to be an agent to which a patient is exposed currently or in the 
past and is believed to have contributed to the provocation of TDt. Many studies deal with 
offending drugs associated with tardive syndromes in general, or TDk, and information for 
TDt has to be extracted or is confused with information for other tardive syndromes. A list 
of drugs that have been associated with the emergence of TDt is provided in Table 2. The 
syndrome may appear while the patient is on the drug, or after the drug’s reduction or dis-
continuation, without being any “safe” period of exposure [7]. It is presumed that any drug 
exerting direct or indirect anti-D2 properties can be incriminated. Regarding antipsychotics, 
the emergence of the syndrome seems to be extremely rare following clozapine or quetiapine 
exposure, probably due to their very low D2 affinity and fast dissociation from the dopa-
mine receptor; in fact, they represent a therapeutic option [26, 27]. Numerous case reports are 
found in the study for several antipsychotic drugs [28–31]. A matter of serious concern is the 
administration of extended release preparations, for example, paliperidone palmitate [32, 33], 
Antipsychotics
 Typical
 Atypical
Antidepressants
Buspirone
Antiepileptics
Lithium
Antiemetics
Calcium-channel blockers
Psychostimulants
 Cocaine
 Pseudoephedrine
Chemotherapeutic agents
Memantine
Table 2. Offending drugs implicated in TDt.
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as in this case, the responsible drug cannot be easily removed or substituted. Classes of anti-
depressants (SSRIs, SNRIs, NASSA, NDRI, and TCAs) probably act by overstimulating of 
the basal ganglia serotonin 5-HT2 receptors, leading to dopamine antagonism, while norad-
renergic hyperactivity might also play a role [22, 24]. Antiemetic and prokinetic agents cen-
trally blocking D2 receptors on the chemoreceptor-trigger zone are also implicated, such as 
substituted benzamides (metoclopramide, clebopride, and cisapride) and prochlorperazine, 
which is a phenothiazine [34]. Calcium-channel blockers (nifedipine, cinnarizine, and flunari-
zine) may alter central dopamine production through N-type calcium channels and produce 
tardive dystonic reactions [35, 36]. On rare occasions, antiepileptics (e.g., carbamazepine [37] 
and lamotrigine [38]), lithium [39, 40], psychostimulants, by altering dopamine neurotrans-
mission (e.g., cocaine and norpseudoephedrine [41–43]), chemotherapeutic agents, possibly 
through a delayed toxic effect on basal ganglia (e.g., 5-fluorouracil and doxorubicin [44]), 
buspirone [45], and memantine administered accidentally at a double than recommended 
daily dose [46] have been reported. Dopamine agonists can cause dystonia in the presence of 
parkinsonian pathology [39]. Anticholinergics have been found to worsen symptoms of TDk 
[47], but, on the contrary, they seem to improve TDt [6].
4. Diagnosis, clinical presentation, and course
The criteria of TDt have been set by Burke et al. and these are the following: (1) the presence of 
dystonia (sustained, involuntary, usually slow-twisting movements), (2) the onset of dystonia 
was during ongoing treatment or within 2 months of discontinuation of antipsychotic drug treat-
ment, (3) in the presence of other tardive syndromes such as akathisia or dyskinesia, dystonia 
should be the main feature, (4) clinical and laboratory evaluation should be provided to exclude 
other causes of dystonia, and (5) negative family history of dystonia [2]. All five are required for 
a definite diagnosis [2, 48]. The authors had studied a sample of 42 patients with TDt, and the 
onset of the symptoms began after 3 days to 11 years of antipsychotic treatment [2]. Kang et al. 
have used the Burke criteria with minor revisions [49]. Tardive dystonia is classified in DSM-5 
under the chapter “medication induced movement disorders and other adverse effects of medi-
cation” as a diagnostic entity separate from tardive dyskinesia [50]. This represents a progress 
from DSM-IV-TR, where it was classified under the collective term “movement disorder not 
otherwise specified.” It is most probable that such a departure will aid better recognition and 
also enhance research. In ICD-10, it is classified as “G24.0, drug-induced dystonia.”
TDt typically presents with sustained involuntary muscle contractions, which cause abnor-
mal postures and twisting movements especially on the upper limbs, neck, trunk, or face [5]. 
It is classified according to the affected body parts as focal (one body part affected), segmen-
tal (two or more body parts which are contiguous), multifocal (two or more distant body 
parts affected), and generalized (affects the trunk and at least two other body parts) [6]. The 
involvement of cranial-cervical area is described in 87% of patients [7], which is the most 
common in TDt, and presents with retrocollis (dystonic cervical movement where the head 
is drawn back), anterocollis (the head is drawn forward), and torticollis (the head is turned 
to the side). Opisthotonous is also a frequent manifestation, with trunk involvement, most 
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evident during walking. The trunk is arched backwards, with the arms at adduction and 
extension and the wrists flexed [6]. Other cases manifest clinically with focal or segmental 
dystonia such as tardive oculogyric crises (involuntary ocular deviations), or involve the jaw 
(jaw deviation), oromandibular area (trismus), and blepharospasm [51]. Pisa syndrome refers 
to a tonic flexion of the trunk to one side of the body, leading to a slight lean, whereas Meige 
syndrome is described as oromandibular dystonia (involuntary and often forceful contraction 
of the muscles of the jaw and tongue) and blepharospasm (involuntary muscle spasms and 
contractions of the muscles around the eyes) [52].
Pain and strange somatic symptoms were described by few patients in the early stages of 
TDt [7]. The involuntary movements of TDt seem to get better or vanish during sleep and 
worsen under stress, leading to a fluctuating picture. They can be partially controlled by 
simple maneuvers such as a sensory trick response, where a gentle touch on the chin or neck 
or a forcible one with certain amount of pressure can alleviate dystonic movements [49, 53].
All forms of dystonia, which include lower limbs only, are more common in idiopathic dys-
tonia and not in TDt [6]. None of patients with TDt had a lower limb involvement without 
face or neck involvement, too [2]. As already mentioned, TDt is frequently co-occurring with 
other tardive syndromes, such as TDk, Tardive akathisia (TDa), Tardive myoclonous (TDm), 
and Tardive tourettism (TDr) (Table 3). Patients with TDt are more aware of their movement 
disorders than patients with TDk [54].
The onset of TDt is insidious, mostly at first with focal dystonia (83%), affecting most frequently 
the face and neck; it may be heralded by increased eye-blinking or tick-like movements, and 
over time, it can evolve to segmental and generalized [7]. The course is progressive for months 
and then persists and remains static for years [2]. Unfortunately, remission rates are low, with 
a mean of 10%, in a mean follow-up period of 6.6 years [2, 5, 7, 49]. Tapering and withdrawal 
of the offending drug is important for remission and increases this possibility fourfold [7].
Studies N Number of patients with more than one 
tardive syndrome
Tardive syndromes
Sachdev et al. [54] 15 9
6
TDt, TDk
TDt, TDa
Burke et al. [2] 42 16 TDt, TDk
Wojcik et al. [55] 32 27
2
TDt, TDk
TDt, TDm
Kang et al. [48] 67 28
21
TDt, TDk
TDt, TDa
Kiriakakis et al. [7] 107 32
24
1
TDt, TDk
TDt, TDa
TDt, TDr
Table 3. Clinical overlap of TDt and other tardive syndromes.
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Prognosis of TDt is poor and disability in patient’s everyday activities frequent. Movement 
disorders and their symptoms affect social life and emotional condition too. Deterioration 
in speech, vision, eating habits, sitting, gait, and sexual ability have been reported [9, 56, 
57]. Oculogyric crises and blepharospasm, and cranial-cervical dystonia, can gravely inhibit 
daily living activities, such as driving and personal grooming, for example, shaving, comb-
ing, or dressing. Muscle contraction and activity may lead to abnormal positions of the body. 
Sometimes, fractures occur, resulting from the way of walking or standing. A potentially 
painful situation can be present [52, 56]. Even though rare, the involvement of laryngeal or 
respiratory muscles can occur in TDk [58] and TDt [59] and can be very distressing or even 
life-threatening.
Social avoidance, isolation, and stigmatization concerns are common in patients with TDt, 
as abnormal postures and contractions impose a strange appearance. Furthermore, work 
productivity, finding an employment, and coping with family roles become compromised. 
Quality of life accordingly deteriorates, to a greater extent in patients with generalized dysto-
nia than in those with focal [60], and is associated with anxiety and depression [61].
5. Differential diagnosis
For the unfamiliar clinician, the diagnosis of TDt can be difficult. Clinical overlap with other 
tardive syndromes could possibly lead to a missed diagnosis, or a misdiagnosis. Strange pos-
tures can be considered as mannerisms in a psychotic patient, and deterioration with anxiety 
together with amelioration with relaxation or sleep can lead to a mistaken diagnosis of con-
version disorder, other psychogenic condition, or hypocrisis.
Differential diagnosis begins with differentiation from other types of movement disorder or 
tardive syndromes, by deciding on the dystonic kind of the symptoms. Then, it must be dis-
tinguished from other primary and secondary dystonias (Table 4) [2, 3, 5, 39, 54, 62].
Acute dystonia
Idiopathic torsion dystonia
Focal dystonia
Secondary dystonias due to focal brain lesions
 Brain injury, tumor, vascular damage, infectious, post-infectious, paraneoplastic
Secondary dystonias due to diffuse brain damage
 Ischemic, hypoxic, metabolic, toxic
Dystonia-plus syndromes
Heredodegenerative dystonia (Wilson ´s disease, Huntington ´s disease, and others)
Table 4. Differential diagnosis of TDt.
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Acute dystonia appears for 48–72 h after the use of neuroleptic drugs. After discontinuation 
or reduction of the responsible drug, it completely resolves within 48 h [2]. Acute dystonic 
reactions impressively respond to the administration of anticholinergics, such as biperiden 
5 mg or procyclidine 5 mg, antihistamines like promethazine 50 mg [20], and benzodiazepines 
like clonazepam 0.5–4 mg.
Idiopathic torsion dystonia may be clinically indistinguishable from TDt. A leg involvement 
would be more suggestive of idiopathic dystonia. Cervical position such as head bent toward 
the shoulder (laterocollis) and torticollis may be seen more frequently in idiopathic dystonia, 
whereas retrocollis (hyperextension of head and neck backwards) is more usually encoun-
tered in TDt [51, 62]. In a recent work, Godeiro-Junior et al. [63] compared a series of 20 
patients with neuroleptic-induced tardive cervical dystonia with a group of patients suffering 
from idiopathic cervical dystonia and found no differences that would be able to differentiate 
them on phenomenological grounds. The authors concluded that previous or current neuro-
leptic exposure remained the critical diagnostic clue, pointing to a diagnosis of TDt. Apart 
from this, the presence of another tardive syndrome, for example, dyskinesia or akathisia, 
also supports this diagnosis. Correct assessment is crucial, not only for management but also 
for legal reasons, in case of a lawsuit for antipsychotic adverse event [64].
6. Pathophysiology
The pathophysiology of TDt has not yet been elucidated and remains speculative to a large 
extent. It has been suggested that it may share some pathophysiologic mechanisms with idio-
pathic dystonia. Basal ganglia seem to represent a central key player in the etiology of primary 
and secondary dystonias, including TDt. Cerebellar abnormalities are probably also impli-
cated, and it has been recently demonstrated that these two structures are directly intercon-
nected, with disynaptic loops [65]. On a receptor and neurotransmitter level, the development 
of tardive syndromes is thought to correlate with dopamine receptor upregulation and hyper-
sensitivity, following their chronic excessive blockade [66, 67]. D2 blockade together with D1 
lower occupancy may lead to sensitization of D1 neurotransmission and a D1/D2 imbalance 
output, resulting in pathological movement [68]. The production of free radicals and oxidative 
stress, abnormalities of GABA input to striatal neurons and altered synaptic plasticity, altered 
serotonin receptor signaling, upregulation of D3 receptors and degeneration of striatal cholin-
ergic neurons are also suggested as the possible contributing mechanisms, but most relevant 
work again does not discriminate between TDt and TDk [69, 70].
A possible insight to the neurobiological processes underlying the dystonic phenomenon may 
be provided by the different potential of typical and atypical antipsychotics to produce more 
severe dystonic symptoms, and in particular by the fact that switching to very low potency 
agents, such as clozapine and quetiapine, seems to ameliorate or even reverse dystonic move-
ments [26]. The concept of atypicality has been introduced early and was initially defined as 
(1) a drug with antipsychotic efficacy at a dose that has a low risk of producing EPS, prolactin 
elevation, and tardive dystonia/dyskinesia, (2) a drug that has a greater affinity for the 5HT-2A 
receptor than for the D2 receptor, and (3) a drug that has a greater efficacy in treating positive, 
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negative, and cognitive symptoms of schizophrenia. Notably, among SGAs, considered to be 
atypical, only clozapine has demonstrated some superior efficacy in symptoms as in (3) [71]. 
It is supposed that 5HT-2A antagonism permits the release of dopamine in the nigrostriatal 
pathway, thus preventing the emergence of motor symptoms, whereas antipsychotic efficacy 
by D2 blocking in the mesolimbic pathway is preserved [72]. Another aspect of atypicality 
refers to the rapid dissociation hypothesis, where atypicality is attributed to the property of 
blocking D2 receptors long enough for antipsychotic efficacy and shortly enough for avoid-
ing EPS. Clozapine and quetiapine uniquely dissociate from D2 receptor fastest. It takes less 
than 60 s to dissociate from 50% of D2-cloned receptors, a tremendously faster process than 
haloperidol, which does so in more than 25 min [73]. In this case, endogenous dopamine can 
bind in D2 receptors, between antipsychotic doses, and it is hypothesized that the system is 
thus allowed to exert the phasic nature of normal dopamine transmission, considered to be 
crucial for normal physiologic actions [74]. On the contrary, typical antipsychotics bind much 
longer on receptors, and the normal phasic dopamine neurotransmission is distorted to a 
much greater extent. It has been demonstrated by PET studies that haloperidol and typical 
antipsychotics produce an increased D2 receptor density in the striatum of humans and ani-
mals [75, 76]. Future research is hoped to elucidate and expand our knowledge on mechanism 
of TDt, with the aim of finding better treatments.
7. Pharmacogenomics of drug-induced dystonia
The term “pharmacogenetics” was first introduced by Friedrich Vogel, in 1959, and refers to 
the association between an individual’s genes and response to a drug or else, the individual-
izing of treatment [77, 78]. Later, in 1997, Marshall introduced the term “Pharmacogenomics” 
which, due to the advances of technology and whole genome-sequencing techniques, refers 
to the impact of multiple genes and specific genetic variations on drug response, including 
maximum efficacy, but also the minimization of adverse drug reactions. This developing field 
is expected to contribute to optimal drug choice, in terms of efficacy and safety [78].
To select an antipsychotic drug or dose, psychiatrists take into account many factors, such 
as the age of the patient, the gender, exercise attitudes, smoking status, liver and renal func-
tion, other comorbidities, and co-medications, [77, 79]. Further, different genetic profiles of 
patients and specifically genetic variations that are associated and affect the pharmacokinetic 
and pharmacodynamics properties of a drug will lead to different response, including effi-
cacy and toxicity. These genetic variations may cause decreased plasma levels, which will 
result in a decreased efficacy, or increased plasma levels, which may lead to the appearance of 
an adverse drug reaction [77]. A variety of publications aim to associate genetic variations of 
genes involved in pharmacokinetics and pharmacodynamics and drug-induced TDt or TDk, 
without discriminating between the two. Research is mainly directed toward the genes that 
metabolize drugs or drug transporters and receptors [79, 80].
One of the most studied and well-defined genes is CYP2D6. One-fourth of all drugs are 
primarily or secondarily metabolized through CYP2D6, including many antipsychotics and 
antidepressants. CYP2D6 in humans is found on chromosome 22q13.1, and until today, more 
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than 100 allelic variants have been identified. The phenotype, depending on the alleles, can 
be Ultra rapid Metabolizer (UM), Extensive Metabolizer (EM), Intermediate Metabolizer (IM), 
and Poor Metabolizer (PM) [77, 80]. Importantly, different ethnicities have different allelic 
distributions and therefore their drug metabolism differs [80].
Although researchers have focused on many genetic variations located on CYP2D6 and their 
association with the development of TD, results are conflicting. There are studies that failed 
to indicate an association between TD and CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, 
CYP2D6*5, CYP2D6*6, CYP2D6*15a, CYP2D6*17 (Ohmori et al. [81]; Ohmori et al. [82]; Arthur 
et al. [83]; Armstrong et al. [84]; Brockmöller et al. [85]; Lohmann et al. [86]), but also studies 
that indicated an association or at least a trend of association between the studied alleles of 
CYP2D6 and TD. A study in 1998, in 100 Japanese patients with schizophrenia, indicated a sta-
tistically significant association in allelic level between CYP2D6*10 and TD, which remained 
significant even after adjustment for variables by regression analysis [82]. The same year, 
another group focused on 45 Caucasian schizophrenic patients of Austrian origin, and the 
potential association between CYP2D6*3, CYP2D6*4, and CYP2D6*5 mutations and TD. There 
was a trend of correlation between CYP2D6 genotype and TD development, and, in particular, 
heterozygotes for one mutation presented a higher risk of TD [87]. Similarly, patients with 
at least one mutation, CYP2D6*1, CYP2D6*3 or CYP2D6*4, indicated a higher incidence of 
TD [88]. A trend of association between PM and TD severity was also detected in the study 
by Andreassen et al. who conducted an investigation of CYP2D6*1, CYP2D6*3, CYP2D6*4, 
CYP2D6*5, CYP2D6*6, and CYP2D6*7 in 100 schizophrenic patients from South-East Scotland 
[89]. Two other studies, which also performed a gender analysis, indicated that female schizo-
phrenic patients with TD had a higher frequency of CYP2D6*10 allele than men [90] and 
that males with a non-functional or a partially functional allele of CYP2D6*1 to CYP2D6*1, 
CYP2D6*10B, CYP2D6*14, CYP2D6*18, CYP2D6*19, CYP2D6*25, CYP2D6*26, CYP2D6*31, 
CYP2D6*36, and CYP2D6*41 had a higher risk of TD than those of wild type [91]. A significant 
association was also found between increased metabolism of FGAs and TD [92]. Finally, in 
the study by Ellingrod et al., in a cohort of 37 Americans with schizophrenia, the larger part 
of smokers with CYP2D6*1/*3, *4 suffered from TD [93].
Researchers have also studied CYP1A2 gene. Studies concerning TD and 734C/A [94–96] as 
well as 2964G/A [94] of CYP1A2 in patients with schizophrenia fail to detect any association. 
However, C homozygotes were found to be associated with higher AIMS scores in two inde-
pendent studies performed in 200 and 2015 [97, 98].
Regarding dopamine receptor genes, DRD1, DRD2, DRD3, and DRD4 receptors have been 
investigated by a variety of laboratories.
In a study of 2011, in which DRD1 and specifically rs5326, rs4532, and rs265975 polymor-
phisms were investigated, only rs4532 was found to be significant, with CC genotype being 
associated with TD [99].
As for DRD2, rs1801028, rs1800497, rs1799732 (Hori et al. [100]; Kaiser et al. [101]; Koning 
et al. [102]; Park et al. [103]), rs1801028 [101, 104], rs1799978, rs1079597, Val96Ala, Leu141Leu, 
Pro310Ser [101], rs1800498 [102, 103], rs6275 [103], and rs6277 [102] did not present any statistically 
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significant association either in allelic or in genotypic level. However, concerning rs1800497 on 
DRD2, there is an older study which was performed in a group of patients with schizophrenia, 
indicating that this polymorphism may affect the development of TD differently [105].
Many scientific groups focused on rs6280, located on DRD3 gene. The majority of the studies 
indicated no association between alleles and genotypes with TD development (Utsunomiya 
et al. [106]; Løvlie et al. [107]; Chong et al. [104]; Gaitonde et al. [108]; Rietschel et al. [109]; 
Garcia-Barceló et al. [110]; Basile et al. [111]; Koning et al. [102]; Segman et al. [112]). However, 
there are four studies which succeed in correlating TD with either the Gly-allele [113], the 
Gly homozygotes [114, 115], and the heterozygotes [116]. Still, a study that studied seven 
candidate genes, including DRD3 and rs9817063, rs2134655, rs963468, rs324035, rs3773678, 
rs167771, rs11721264, rs167770, rs7633291, rs1800828 polymorphisms, as well as DRD4 gene 
and specifically, rs3758653, failed to prove any association with antipsychotic-induced move-
ment disorders [117].
Concerning serotonergic receptors, HTR2A, HTR2C, and HTR6 genes have been investigated. 
HTR2A gene and especially rs6313, rs6311, and rs6314 were the subject of research in many 
groups. According to some studies, there was no association between TD development and 
rs6313, rs6311, and rs6314 [102, 111, 118]. Nevertheless, a study of 2011 regarding rs6313 
showed a relation between T allele and TD development [119], whereas a study of 2001 found 
higher frequencies of T homozygotes in patients without TD and also allelic differences 
between patients with and without TD [120]. Segman and his group indicated that patients 
with TD had higher frequencies of 102C (rs6313) and 1438G (rs6311) alleles and also that CC 
(rs6313) and GG (rs6311) were associated with higher AIMS scores [121].
Proceeding to HTR2C, ser-allele of polymorphism rs6318, located in this gene, was found to 
be more common in patients with TD [112], but also rs6318 indicated no statistical significance 
in two other studies [102, 119]. Further, rs3813929 indicated no association, and rs518147 was 
more frequent in patient with TD than those without [102, 122]. The study of Bakker studied 
rs569959, rs17326429, rs12858300, rs4911871, rs5946189, and rs1801412 polymorphisms of 
HTR2C and found no association between them and TD, either in genotype or in allele level 
[117]. HTR6 and rs1805054 were studied in a group of 173 Japanese schizophrenia patients, 
and no association was observed with TD development [123].
Summing up, there are significant genetic associations between patients with schizophrenia 
that suffer from drug-induced TD, implicating that dopamine and serotonin systems, as well 
as CYP genes, participate in TD development. All included studies performed genotyping 
analysis with well-established and accurate laboratory techniques, like PCR-RFLP, sequenc-
ing, and TaqMan assay, whereas studied cohorts included patients of different ethnicities 
and races, including Caucasians, Chinese, and Japanese patients, diagnosed according to 
the diagnostic criteria of the Diagnostic Statistical Manual or the International Classification 
of Diseases. Assessment of TD was mainly performed using the Abnormal Involuntary 
Movement Scale (AIMS). In many studies, the study population was not large enough to 
achieve a statistically significant association. For this reason, studies in larger sample sizes 
need to be done in order to shed more light in the contribution of genetic background in 
patients who face drug-induced TD.
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Furthermore, the majority of studies do not distinguish the terms “dystonia” and “dyskine-
sia.” Most of these studies concern dyskinesia, which also includes cases of dystonia, and it is 
difficult to separate them. Future research with better defined studies differentiating between 
the two conditions is necessary for the better definition of outcomes. Also, factors such as 
advanced age, gender, ethnicity, dose and drug duration, symptoms, smoking status, alcohol 
use, co-medication, comorbidities, and family history of psychiatric disorders or TD are risk 
factors associated with the development of TD [124] and should be taken into consideration 
when investigating the correlation between TD and genetic factors.
8. Treatment
The best pathway to care is prevention, and for a difficult to treat condition such as TDt, 
prevention is of paramount importance. Keeping this in mind, increased guardedness must 
distinguish clinical care for the selection of antipsychotic treatment. Rational use of antipsy-
chotics, that is, using as indicated and not for doubtful reasons, caution to use in mood dis-
orders, not using without a clear indication, not using for longer than needed, should guide 
clinical decisions. High dosages and polypharmacy should be avoided. Atypical antipsychot-
ics should be preferred over typical ones, even though there is some debate concerning an 
increased risk for metabolic syndrome, with certain SGAs [125]. Therapeutic levels of lithium 
and antiepileptics should be monitored and kept within the recommended range; the use of 
an antiemetic that passes the blood-brain barrier at a lower extent, for example, domperidone 
instead of metoclopramide, would be wise [35].
When TDt has already been established, a first option would be to lower the dose or stop the 
offending agent, if the condition of the patient allows it, or substitute the responsible drug 
with another agent with better side-effect profile. Correct assessment of the patient must take 
into account the fluctuating course and diurnal variation of dystonia. In bipolar patients, it 
gets worse during depressive phases [16]. There are reports of SGAs, including clozapine (as 
monotherapy or administered with clonazepam), olanzapine, risperidone, quetiapine, aripip-
razole, ziprasidone, amilsulpiride, and perospirone, being effective as a treatment of TDt [52]. 
However, switching from FGAs to SGAs as a class has not been consistently proven to benefit 
[27]. Switching from the offending drug to quetiapine or clozapine seems to make more sense, as 
both drugs have very low affinity for D2 receptors and are not expected to induce dystonic reac-
tions themselves, but only extremely rarely. Recent studies (one open label and one case series, 
for quetiapine and clozapine, respectively) [26, 126] have demonstrated efficacy, but evidence 
remains insufficient to make a strong recommendation. Choosing between the two favors que-
tiapine, because of the serious side effects associated with clozapine (e.g., agranulocytosis) [26].
If the above strategies are insufficient, or not possible, other options can be employed [16]. 
Several medications have been used to treat dystonia, and the therapeutic approaches include 
pharmacologic treatment and other types of interventions such as chemodenervation with 
botulinum toxin, surgery, deep-brain stimulation (DBS), physical, and supportive methods. 
There are lacking guidelines concerning the selection of dystonia treatment, so the clinical 
practitioner may choose between recommended therapeutic methods, often guided by per-
sonal experience and the patients’ needs [127].
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Botulinum toxin can be a therapeutic option, since it has been shown to be helpful in the treat-
ment of several dystonic manifestations like blepharospasm [128], oromandibular dystonia 
[129], laryngeal dystonia [130], cervical dystonia [131], and writer’s cramp and other limb 
dystonias [132].
Tetrabenazine, a dopamine-depleting agent, can also be an effective treatment for some 
patients with dystonia, with a starting dose of 25 mg daily, and titrated up to a target dose 
up to 100 mg daily. It seems that tetrabenazine is more effective in patients with TDt than 
those with idiopathic dystonia [133]. Adverse reactions include drowsiness, parkinson-
ism, depression, insomnia, agitation, anxiety, and akathisia [134]. More recent studies have 
examined deutetrabenazine and valbenazine, which, like tetrabenazine, are also selective 
vesicular monoamine transporter 2 (VMAT2) inhibitors, but better tolerated than tetra-
benazine. The two substances have been very recently approved for the treatment of TDk 
(which is considered to include TDt) by the US Food and Drug Administration [27].
Acetylcholine-related drug use is one of the most common treatment strategies in dystonia, 
and they are frequently prescribed for dystonic reactions (including drug-induced dystonia). 
Anticholinergics such as trihexyphenidyl, starting from low doses such as 2 mg daily and a 
final dose ranging from 6 to 40 mg daily [134], benzatropine, biperiden, procyclidine, orphen-
adrine, and ethopropazine [135], have been broadly used in many types of dystonia, and 
the effectiveness seems to be quite satisfying. However, there are limitations for their use, 
regarding less tolerability of anticholinergic use in older adults and because high doses are 
demanded [136]. Their typical side effects include cognitive dysfunction, memory impair-
ment, depression, confusion, dry mouth, constipation, urinary retention, blurred vision, and 
deterioration of narrow-angled glaucoma.
Baclofen has been reported to be effective in patients with TDt [137], especially in patients 
with blepharospasm, compared to other types of dystonic reactions. Drowsiness, dizziness, 
nausea, and fatigue are considered to be the drug’s main adverse reactions [138].
Benzodiazepines such as alprazolam, clonazepam, chlordiazepoxide, and diazepam have 
been used in the treatment of dystonia, according to multiple small or retrospective studies 
[134]. They act as GABA receptor agonists, as they enhance GABA receptor function and 
GABA neurotransmission. Most common side effects include sedation, cognitive impair-
ment, abuse, tolerance, depression, ataxia, and motor disturbances. Vitamin E has also been 
proposed as a potential treatment in TDt, and dystonic symptoms improvement has been 
reported after its administration [139].
Deep-brain stimulation (DBS) has been proposed as a safe and promising treatment for 
patients suffering from disabling and refractory tardive dystonia, resulting in rapid and long-
term improvement in those patients [140].
9. Conclusions
Tardive dystonia is a motor tardive adverse event, resulting from exposure to anti-D2 agents, 
mostly antipsychotics. It is frequently debilitating and treatment resistant, and although 
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progress has been made regarding clinical diagnosis and recognition, the neurobiological 
basis of the condition remains elusive and offered treatment far from satisfactory. Pioneering 
work must be guided toward a better understanding of normal movement control and patho-
physiological processes of abnormal and dystonic movements. Pharmacogenomic studies 
will be further contributing to identify genetic variations associated with the appearance 
of drug-induced TDt in the future and are expected to lead to more individualized selec-
tion of treatment for each patient, aiming to provide a better outcome. In total, several lines 
of research are ultimately hoped to usher in better care for people in need of antipsychotic 
treatment.
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